The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer

Primer Autor
Janjigian, Yelena Y.
Co-autores
Kawazoe, Akihito
Yanez, Patricio
Li, Ning
Lonardi, Sara
Kolesnik, Oleksii
Barajas, Olga
Bai, Yuxian
Shen, Lin
Tang, Yong
Wyrwicz, Lucjan S.
Xu, Jianming
Shitara, Kohei
Qin, Shukui
Van Cutsem, Eric
Tabernero, Josep
Li, Lie
Shah, Sukrut
Bhagia, Pooja
Chung, Hyun Cheol
Título
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
Editorial
NATURE PORTFOLIO
Revista
NATURE
Lenguaje
en
Resumen
Human epidermal growth factor receptor 2 (HER2, also known as ERBB2) amplification or overexpression occurs in approximately 20% of advanced gastric or gastro-oesophageal junction adenocarcinomas(1-3). More than a decade ago, combination therapy with the anti-HER2 antibody trastuzumab and chemotherapy became the standard first-line treatment for patients with these types of tumours(4). Although adding the anti-programmed death 1 (PD-1) antibody pembrolizumab to chemotherapy does not significantly improve efficacy in advanced HER2-negative gastric cancer(5), there are preclinical(6-19) and clinical(20,21) rationales for adding pembrolizumab in HER2-positive disease. Here we describe results of the protocol-specified first interim analysis of the randomized, double-blind, placebo-controlled phase III KEYNOTE-811 study of pembrolizumab plustrastuzumab and chemotherapy for unresectable or metastatic, HER2-positive gastric or gastro-oesophageal junction adenocarcinoma 22 (https://clinicaltrials.gov, NCT03615326). We show that adding pembrolizumab to trastuzumab and chemotherapy markedly reduces tumour size, induces complete responses in some participants, and significantly improves objective response rate.
Tipo de Recurso
artículo original
doi
10.1038/s41586-021-04161-3
Formato Recurso
PDF
Palabras Claves
NIVOLUMAB PLUS CHEMOTHERAPY
GASTROESOPHAGEAL JUNCTION
RESPONSE CRITERIA
OPEN-LABEL
TRASTUZUMAB
ESOPHAGEAL
THERAPY
Ubicación del archivo
http://dx.doi.org/10.1038/s41586-021-04161-3
Categoría OCDE
Ciencias Multidisciplinarias
Materias
QUIMIOTERAPIA NIVOLUMAB PLUS
UNIÓN GASTROESOFÁGICA
CRITERIOS DE RESPUESTA
ETIQUETA ABIERTA
TRASTUZUMAB
ESOFÁGICA
TERAPIA
Disciplinas de la OCDE
Oncología
Biotecnología Relacionada con la Salud
Farmacología y Farmacia
Título de la cita (Recomendado-único)
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
Página de inicio (Recomendado-único)
727
Identificador del recurso (Mandatado-único)
artículo original
Versión del recurso (Recomendado-único)
version publicada
License
CC BY 4.0
Condición de la licencia (Recomendado-repetible)
CC BY 4.0
Derechos de acceso
restringido
Access Rights
restringido
Id de Web of Science
WOS:000730529300009
Colecciones
Colección Publicaciones Científicas
Estadísticas del documento
0 visitas
Métricas externas
Altmetric
Dimensions